Alpha -Tocopherol Acetate Dl- Beta -Carotene 5-Met

證據等級: L5

預測適應症: 0 個

Multivitamin-Mineral Complex: No Predicted New Indication Available

One-Sentence Summary

This candidate is a comprehensive multivitamin-mineral combination containing 18 active ingredients, including fat-soluble vitamins (Vitamin D3, E, beta-carotene), water-soluble vitamins (B1, B2, B3, B6, B12, C, biotin, folic acid, 5-MTHF), and trace minerals (iron, zinc, copper, magnesium, calcium, potassium iodide). The TxGNN model did not generate any predicted new indications for this multi-component combination. No clinical trial or literature evidence could be retrieved, and this candidate is currently not marketed in Taiwan, making a full repurposing evaluation infeasible at this stage.

Quick Overview

Item	Content
Original Indication	Unknown (no regulatory filings on record)
Predicted New Indication	N/A — no TxGNN predictions generated
TxGNN Prediction Score	N/A
Evidence Level	Not Evaluable
Taiwan Market Status	✗ Not Marketed
Number of Licenses	0
Recommended Decision	Hold

Why is This Prediction Not Available?

The query target is not a single molecular entity but an 18-component nutritional formula combining vitamins, provitamins, and inorganic mineral salts. The TxGNN knowledge graph is designed to operate on individual drug nodes (DrugBank IDs); a compound mixture without a unified DrugBank entry cannot be mapped to the knowledge graph, which explains why predicted_indications returned an empty array.

Furthermore, while individual components such as folic acid, cholecalciferol, and ascorbic acid each have well-characterised mechanistic roles in haematopoiesis, bone metabolism, and antioxidant defence, the combination as a single unit does not correspond to any disease-drug relationship node in the TxGNN graph. Generating a repurposing prediction would require either splitting the combination into individual INN queries or defining a virtual composite node — neither of which was performed in this pipeline run.

Clinical Trial Evidence

Currently no related clinical trials registered for this combination as a unified candidate.

Literature Evidence

Currently no related literature available for this combination as a unified TxGNN candidate.

Taiwan Market Information

This combination has 0 regulatory licenses on record in the Taiwan FDA (TFDA) database. No approved product data is available to display.

Safety Considerations

Please refer to the package insert for safety information.

No drug-drug interaction data was returned (DDI query status: not found). No key warnings or contraindications data is available in the current Evidence Pack.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN pipeline cannot process an 18-component mixture as a single drug entity because no unified DrugBank ID exists for this combination, resulting in zero predictions and zero retrievable evidence. A repurposing evaluation is not feasible without resolving the data structure issues first.

To proceed, the following is needed:

Decompose the query: Re-run TxGNN predictions for each of the 18 individual INNs separately (e.g., folic acid → DB00158, cholecalciferol → DB00169, ascorbic acid → DB00126) and aggregate results
Assign DrugBank IDs: Map each component to its individual DrugBank entry so the knowledge graph can be traversed
Define the clinical question: Clarify whether the goal is repurposing the full combination or evaluating individual micronutrients for specific indications
Regulatory verification: Confirm whether any single-component or similar combination products are filed under TFDA or US FDA (NDA/OTC monograph)
MOA documentation: Retrieve mechanism-of-action data for each component from DrugBank to support mechanistic plausibility analysis
Safety data: Download individual component package inserts to populate key warnings and contraindication fields
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.